患者对数字干预管理心力衰竭药物的看法:VITAL-HF试点项目
Marc D Samsky1, Renee Leverty2, James M Gray3
1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Journal of clinical medicine
|July 29, 2023
概括
一个数字健康工具有效地支持心力衰竭的指导指导医学疗法 (GDMT) 减少排气分数 (HFrEF). 这种以患者为中心的方法改善了药物管理,并为HFrEF患者提供了安全.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 医疗保健服务研究 医疗服务研究
背景情况:
- 用于心力衰竭的指南导向医疗疗 (GDMT) 使用心力衰竭与减少喷射率 (HFrEF) 是次优的.
- 需要有效的策略来改善HFrEF患者的GDMT坚持和定位.
研究的目的:
- 评估数字健康工具在增强HFrEF患者的GDMT中的有效性.
- 评估患者对使用数字工具来管理HFrEF药物的观点.
主要方法:
- 一项试点研究涉及使用移动健康平台的有症状的HFrEF患者 (LVEF ≤40%).
- 参与者使用连接的血压袖子,并完成了症状调查.
- 健康教练提供支持,临床医生通过数字平台管理GDMT定位.
主要成果:
- 12名参与者完成了这项研究,平均年龄为52.5岁,LVEF为25%.
- 这项研究促进了10次GDMT启动,52次升级和13次降低.
- 患者采访显示,在管理病情时,增加了安全性,舒适性和赋权.
结论:
- 使用数字健康工具对HFrEF进行GDMT的远程定位是可行的.
- 这种以患者为中心的方法提高了药物管理和患者参与HFrEF护理.
相关概念视频
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure VII: Nursing Interventions
96
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
96
Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Heart Failure I: Introduction
16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16


